Anixa Biosciences
ANIX
44 hedge funds and large institutions have $15.8M invested in Anixa Biosciences in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 6 closing their positions.
103% more call options, than puts
Call options by funds: $65K | Put options by funds: $32K
3% more capital invested
Capital invested by funds: $15.4M → $15.8M (+$394K)
0.06% more ownership
Funds ownership: 11.79% → 11.85% (+0.06%)
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
8% less funds holding
Funds holding: 48 → 44 (-4)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$371K |
| 2 |
Jane Street
New York
|
+$271K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$136K |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
+$87.6K |
| 5 |
VF
Virtu Financial
New York
|
+$80.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$205K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$159K |
| 3 |
Renaissance Technologies
New York
|
-$116K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$96.5K |
| 5 |
CAM
Concorde Asset Management
Ann Arbor,
Michigan
|
-$65.9K |
ANIX Hedge Fund Activity: Q1 2023 in Review
44 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q1 2023, worth a combined $15.8M — up 2.6% from $15.4M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ANIX and 4 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 9 added.
The largest buyer was Susquehanna International Group, adding an estimated $371K. The largest seller was BlackRock, cutting an estimated $205K.
- 44 institutional investors held Anixa Biosciences (ANIX) as of Q1 2023, down from 48 in Q4 2022.
- Funds reported $15.8M of Anixa Biosciences stock for Q1 2023, up 2.6% quarter-over-quarter.
- 4 funds opened new Anixa Biosciences positions in Q1 2023 and 6 closed out, a net change of -2 holders.
- The largest Anixa Biosciences buyer in Q1 2023 was Susquehanna International Group, an estimated $371K added.
- The largest Anixa Biosciences seller in Q1 2023 was BlackRock, an estimated $205K sold.
Based on aggregated 13F filings for Q1 2023.